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Ventilator associated pneumonia (VAP) represents a
major threat to the recovery of patients receiving
mechanical ventilation, and is a difficult diagnostic and
therapeutic challenge for critical care physicians. VAP
occurs in 5-25% of all patients with different varieties of
respiratory failure, and its incidence exceeds 70% in
patients who die of adult respiratory distress syndrome
(ARDS).
The microaspiration of bacteria from the oropharynx
is an important step in the pathogenesis of VAP;
colonization of a patient’s oropharynx with multiresistant nosocomial pathogens does not make the
problem easier to solve. There are several endogenous
and exogenous factors behind oropharyngeal colonization
and despite several preventive measures and efforts to
find a solution are continuing. Recent studies on VAP have
Pseudomonas
aeruginosa,
demonstrated
that
Haemophilus influenzae, Staphylococcus aureus,
Klebsiella pneumoniae, Enterobacter spp. and Escherichia
coli are the leading pathogens but anaerobes have also
been isolated in levels of up to 30%.
Conventional criteria for the diagnosis of VAP include:
new or progressing pulmonary infiltrate findings as well
as fever leukocytosis and purulent tracheal secretions.
However, none of these signs are very sensitive or
specific. Therefore, for the above reasons, prevention and
therapy are considered essential (1).
I. Prevention
Because VAP has been associated with increased
morbidity and mortality and greater costs, prevention
remains an important goal for all intensivists.

Preventative strategies can be divided into five main
categories:
Identification and “control” of risk factors
Classic infection control measures
Strategies aiming to limit airway colonization
Strategies that improve host defense mechanisms
Other measures

1. Identification and “control” of risk factors
Various risk factors for VAP have been identified.
They include old age, severity of injury or illness, length
of hospital stay prior to ICU admission, duration of
mechanical ventilation or length of ICU stay, supine body
position, and type of comorbidity. Underlying chronic
cardiorespiratory disease, neurologic injury and trauma as
well as prior administration of corticosteroids and prior
inappropriate antibiotic treatment also predispose
patients to VAP. Identification of potentially modifiable
risk factors for VAP at the institutional level and
development of strategies to modify or prevent the
occurrence of these risk factors is a significant preventive
measure. Although risk factors for acquiring VAP have
been well defined, diagnosis of VAP remains controversial
and its actual incidence appears to be unchanged over the
past two decades (2-5). As a result, patients are often
treated empirically with antibiotic regimens based on
suspected pathogens.

215

Ventilator Associated Pneumonia in Critically Ill Patients: Prevention and Treatment

2. Classic infection control measures
Prevention of VAP relies on basic infection control
practices. General infection control measures remain the
cornerstone of infection prevention in intensive care
units. Furthermore, hand washing remains the
cornerstone of ICU-acquired infection prevention, and it
is a simple but very effective preventive measure. In
addition, infection control programs employing
combinations of interventions aimed at preventing both
colonization of the aerodigestive tract with pathogenic
bacteria and aspiration have been shown to be successful
and cost effective.

3. Strategies limiting airway colonization
Colonization of the oropharynx with pathogens and
ongoing aspiration seem to be required for the
development of VAP. Oropharyngeal colonization is
pivotal in the pathogenesis of VAP, while gastric and
intestinal colonization appear to be less important than
previously believed. Oropharyngeal colonization with
several pathogens and micro-aspiration of colonized
oropharyngeal secretions is a major cause of early-onset
VAP. Prolonged mechanical ventilation (>5 days) and
administration of broad-spectrum antibiotics increase the
risk for late-onset VAP, which is more likely to be related
to Gram-negative bacteria.
Realization that the pathogenesis of VAP requires
aspiration of contaminated secretions, originating from
the aerodigestive tract and ventilator circuit, helps
highlight the role of cross-infection and the importance of
standard infection control procedures.
Many specific strategies interfering with colonization
have been studied. So far, only the use of topical nonabsorbable antibiotics, either of the whole digestive tract
or the oropharynx, has been proven successful in
decreasing the incidence of VAP. However, the effect on
patient survival was disappointing. In addition, there is risk
of selecting antibiotic-resistant bacteria. For these reasons,
the widespread use of these strategies is limited (6).
3.1 Subglottic secretion drainage
There are reports that the use of endotracheal tubes
with the possibility of intermittent or continuous
aspiration of subglottic secretions led to a significantly
lower incidence of VAP in patients receiving prolonged
(>72 h) mechanical ventilation (7,8). Unfortunately, the
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mortality rate and lengths of stay in the ICU and hospital
did not appear to be significantly influenced by the use of
this intervention.
Despite the large volume of extant literature, many
questions remain unanswered. Which patients benefit
from continuous subglottic suctioning? Do certain
surgical procedures predispose patients to VAP more than
others? Furthermore, much research has generally been
in the form of single reports that need to be replicated in
larger multicenter trials. For this reason, further studies
are warranted to confirm the efficacy of this system.
3.2 Pharmacologic strategies aiming to reduce
colonization of the aerodigestive tract with
pathogenic bacteria
Aerosolized antibiotics
Wood et al. administered aerosolized ceftazidime
(250 mg every 12 hours) or placebo (normal saline) for
up to 7 days. The frequency of VAP in patients receiving
aerosolized ceftazidime was 73% lower than that in
patients receiving placebo at ICU day 14 (15% vs. 55%,
P = 0.02), and 54% lower for the entire ICU stay (30%
vs. 65%, P = 0.02) (9).
Biofilm formation routinely occurs on endotracheal
tubes and is considered an important factor promoting
the occurrence of VAP. Unfortunately, there are no
current interventions that have the ability to prevent
biofilm development on the endotracheal tube as well as
within the airways of patients receiving mechanical
ventilation.
Adair et al. compared the efficacy of nebulized
gentamycin (80 mg in 4 ml of normal saline every 8 h),
with that of parenteral cefotaxime or cefuroxime in
preventing the formation of endotracheal tube (ET)
biofilm. Nebulized gentamycin attained high
concentrations in the ET lumen and was more effective in
preventing the formation of biofilm than any parenterally
administered cephalosporin and therefore may be
effective in preventing VAP in mechanically ventilated
patients (10).
Chemicals aimed at blocking gene products from
bacteria forming biofilms, antibodies blocking adhesion of
bacteria, via fibronectin-binding protein, and the use of
specialized coatings blocking bacterial adherence may
offer the possibility to block biofilm formation in the
endotracheal tubes in mechanically ventilated patients and
reduce the incidence of VAP.
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In a recent study, mechanically ventilated trauma
patients who selectively received local decontamination
for the subglottic area, using a continuous infusion of a
suspension containing three non-absorbable antibiotics
(polymyxin, tobramycin, and amphotericin B), developed
VAP at a lower rate compared to controls (11).
4. Strategies that
mechanisms

improve

host

defense

Early nutrition is the most important strategy aiming
to
improve
host
defense
mechanisms.
Immunostimulatory therapies, such as interferon and
granulocyte colony stimulating factor, require further
research to confirm their role in the prevention and/or
management of VAP (12).
5. Other preventive measures
5.1 Chest physiotherapy
Chest physiotherapy in ventilated patients is
independently associated with a lower incidence of VAP.
This suggested benefit of physiotherapy in the prevention
of VAP requires confirmation by a larger randomized
controlled trial (13).
5.2 Stericath closed suctioning system
There are reports that the use of Stericath reduced
the incidence of VAP without demonstrating any adverse
effects (14).
5.3 Strategies attempting to decrease the
occurrence of aspiration: Positioning of patients in a
semirecumbent position
When possible, patients receiving ventilation should be
positioned at a 45° head-up angle to decrease the risk of
the aspiration of gastric contents.
5.4 Kinetic beds
Modalities, such as rotating or kinetic beds, early
bronchoscopy, and changes in ventilator management,
have not been shown to be useful (15). In addition,
studies of "early" tracheostomy have been unable to
define both the optimal timing of tracheostomy and its
effect in decreasing VAP.
5.5 Circuits - humidifiers
Several studies have reported no change in VAP rates
when circuits are only changed on an at-needed basis.
There is also evidence that passive humidifiers and closed

suction catheters do not need to be changed on a daily
basis.
5.6 Selective digestive decontamination (SDD)
Selective digestive decontamination is associated with
a reduction in the incidence of VAP, but the mortality rate
remains largely unaffected, while the selection of
antibiotic-resistant pathogens is a potential disadvantage.
SDD remains controversial despite more than 30
prospective randomized trials and 6 meta-analyses.
Routine SDD in ICU is discouraged. SDD is contraindicated
in ICUs with endemic resistant strains, while
decontamination of the oropharynx appears to be equally
effective (16).
5.7 Stress ulcer prophylaxis
In a recent study, no difference in the incidence of
VAP, macroscopic stress ulcer bleeding or mortality was
found between mechanically ventilated pediatric patients
treated with ranitidine, omeprazole or sucralfate for
stress ulcer prophylaxis and other subjects not receiving
the same treatment (17).
5.8 Non-invasive ventilation
Several studies have demonstrated that non-invasive
ventilation reduces the incidence of nosocomial infections,
including VAP, and antibiotic use, compared to
conventional mechanical ventilation (18,19). Non-invasive
ventilation comes closest to accomplishing prevention of
both colonization of the aerodigestive tract with
pathogenic bacteria and aspiration.
II. Treatment
Once VAP develops, treatment is usually supportive
along with the administration of antibiotics.
Antibiotic Therapy of Ventilator-Associated
Pneumonia Initial empiric therapy
Several studies have emphasized the importance of
early antibiotic therapy in the management of patients
with clinically suspected VAP (20,21). Other studies have
shown that patients who are initially treated inadequately
had poorer outcomes than did those receiving adequate
therapy at the beginning. Clinicians, therefore, are faced
with the following options: first, to treat all patients with
suspected VAP early, preferably with a combination of
broad-spectrum antibiotics at high doses, in order to
cover the most likely causative microorganisms and
overcome potential resistance problems. Alternatively, a
217
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more conservative policy can be followed at the risk of
exposing some ICU patients to a delay in therapy or
inadequate treatment.
There are actually two challenges for intensivists:
first, to decide when and which patient should be treated,
and second to select which antibiotics to prescribe
empirically. For the first challenge, Singh et al. propose a
strategy by which all patients with suspected VAP are
treated empirically with one antibiotic (e.g., ciprofloxacin)
(22). After 3 days of therapy, it is withdrawn in all
patients with a low likelihood of pneumonia, as assessed
by the clinical pulmonary infection score (score <6). This
approach, while treating all patients with suspected VAP,
has the merit of limiting the administration of
unnecessary antibiotic therapy. A more sophisticated
approach of administering antibiotics in a patient with
suspected VAP is to combine clinical data (fever and
purulent tracheal secretions) and laboratory data
(pulmonary infiltrates, leucocytosis and hypoxemia) with
the results of direct examinations (Gram stain) from
bronchial secretions or from bronchoalveolar lavage
samples.
For the second challenge, the selection of initial
appropriate antibiotic therapy appears to be an important
determinant of clinical outcomes. However, there is a
critical question: how should the selection of empiric
antibiotic therapy proceed? Although ciprofloxacin was
effective in the study performed by Singh et al., this
choice can be questioned. Although ciprofloxacin is usually
effective against enterobacteriaceae, Haemophilus
influenza, and some Staphylococcus spp., it is ineffective
against streptococci, Pseudomonas aeruginosa and
Acinetobacter.
In a recent study, Fowler et al. suggested that
piperacillin-tazobactam could be the most appropriate
empiric therapy for suspected VAP. The favorable results
associated with piperacillin-tazobactam (possibly in
combination with an aminoglycoside), especially in
patients with suspected late-onset pneumonia, have been
due to its broad spectrum of activity, or to a lower level
of resistance emergence and superinfection during or
after therapy. However, the authors did not demonstrate
improved outcomes associated with appropriate vs.
inappropriate therapy, or with combination therapy vs.
monotherapy (23). Evidence-based guidelines suggest
that piperacillin-tazobactam may be the most effective
single agent for the empiric treatment of VAP (24).
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Several clinical trials compared piperacillin-tazobactam
with ceftazidime (both in combination with an
aminoglycoside) and found that the former was at least
as effective as the latter (25,26). Thus, could piperacillintazobactam be considered a standard therapy for all
patients with clinical suspicion of VAP? Or, is it better to
follow an individualized antibiotic strategy according to
the specific condition and risk factors in combination with
specific institutional epidemiological surveillance and
resistance patterns?
According to the guidelines of the American Thoracic
Society, the initial antibiotic therapy should be based on
specific risk factors that influence the spectrum of
causative microorganisms in patients with VAP (27). In
patients with a high probability of infection due to
multiresistant bacteria, such as in late-onset pneumonia,
in those who have received prior antibiotic treatment, or
in those who have had prolonged ICU stay before
developing VAP, a combination antimicrobial therapy is
recommended with antibiotics active against
Pseudomonas aeruginosa, Acinetobacter spp., and
possibly methicillin-resistant Staphylococcus aureus
(MRSA). Some patients may be changed to monotherapy,
based on clinical response and the results of pertinent
cultures available at days 2 and 3.
Several other approaches have been proposed, mainly
based on the use of specific diagnostic techniques,
resulting in the treatment of fewer patients with clinically
suspected VAP (28). The selection of antibiotic regimen is
mainly based on the timing of VAP onset in reference to
the start of mechanical ventilation, prior antibiotic use
during the current hospitalization, results of appropriate
diagnostic tests, as well as the most common bacterial
pathogens isolated, and the antimicrobial resistance
pattern of the specific ICU (29). Prescribing an initial
broad-spectrum antibiotic regimen in order to cover all
likely pathogens may result in improved clinical outcome.
Initial combinational antimicrobial therapy, particularly
aimed against antibiotic-resistant Gram-negative bacteria
(e.g., Pseudomonas aeruginosa and Acinetobacter spp.)
and MRSA, offers the greatest likelihood of providing
adequate initial treatment. However, unless supported by
appropriate cultures, such broad-spectrum antibiotic
regimens should not be administered unnecessarily for a
prolonged period in order to avoid the emergence of
antibiotic-resistant infections.
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Some authorities suggest that it is necessary to keep
unit-specific microbiological data to guide the empiric
therapy of suspected VAP. The use of unit-specific
microbiological information can potentially influence
antibiotic prescriptions in order to reduce the
administration of inadequate or ineffective antimicrobial
treatment. Thorough knowledge of ICU antibiotic
resistance patterns should be available and applicable
when choosing empiric therapy and awaiting culture
results. If initial broad-spectrum therapy is to be
instituted, its de-escalation is also imperative once
microbiological and clinical response data become
available (30).
If empiric therapy is administered by means of highly
effective bactericidal agents, the emergence of resistance
could theoretically be minimized. The Center for Disease
Control and Prevention suggested that the optimization
of antibiotic use can be enhanced by education about
appropriate antibiotic use and by providing data to
physicians about the resistant organisms seen in their
own ICU, as part of an ongoing surveillance program,
aimed to minimize the risk of antibiotic resistance.
Distinction of VAP
There are three important determinants that can be
used to guide the selection of empirical therapy in
patients with suspected VAP: the timing of onset of VAP
relative to hospital admission (early vs. late VAP); the
prior administration of antibiotics; and specific
institutional epidemiological data. The distinction between
early VAP (within the first 5 ICU days) and late-onset
pneumonia is a major determinant of the etiology,
provided that the patient has no recent hospitalization.
According to a recent American Thoracic Society
consensus statement, the pathogens usually involved in
early-onset VAP are Haemophilus influenza, methicillin sensitive Staphylococcus aureus (MSSA), and
Streptococcus pneumoniae, and anaerobes (in selected
circumstances). In this situation, a second-generation
cephalosporin or a combination of ampicillin or
amoxycillin with a β-lactamase inhibitor will suffice.
If the patient develops late-onset VAP or has received
broad-spectrum antibiotics, the most likely pathogens are
Klebsiella, Enterobacter, Acinetobacter, Pseudomonas
aeruginosa or MRSA, all of which are likely to be resistant
to most antibiotics administered (31). In this instance, it
is very difficult to predict the microorganisms that may be

involved and their susceptibility profile. For this reason, a
combination of one antipseudomonal penicillin plus a βlactamase inhibitor, or aztreonam with an aminoglycoside
or fluoroquinolone, or a three-agent combination empiric
therapy with a β-lactam, an aminoglycoside, and
vancomycin or teicoplanin for severely ill patients with
suspected MRSA infection is commonly prescribed
pending culture results, unless a more targeted approach
can be guided by the direct examination of bronchial
secretions showing a single pathogen.
Directing antimicrobial therapy toward the most
common pathogens with certain antibiotic regimens may
improve survival, and reduce the emergence of resistance
(32,33). Although most clinicians direct empiric therapy
toward Gram-negative aerobic bacteria and staphylococci,
the most commonly isolated microbes, there is a
considerable variation in management of cases with a
high suspicion of VAP. Aminoglycosides are also
recommended in the initial empiric treatment of VAP.
Aggressive aminoglycoside administration within the first
days has been associated with high peak serum levels and
higher alveolar levels that result in an earlier resolution of
VAP (34).
Difficulties in VAP diagnosis
One of the most difficult issues involving the
investigation of VAP is the confirmation of diagnosis.
Although directed sampling procedures (bronchoscopy
and BAL) may improve outcome, current guidelines do
not mandate their use and VAP is still predominantly
diagnosed using clinical criteria.
Under the scope of evidence showing that initial
appropriate antibiotic therapy is crucial for improving the
prognosis of patients with VAP, some investigators have
evaluated whether microbiological data, obtained by noninvasive or invasive bronchoscopic procedures can be used
to modify antibiotic therapy. When the prognostic value
of this strategy has been evaluated (i.e. changing from
inadequate to adequate antibiotic therapy), most studies
have found no improvement in mortality. Sanchez-Nieto
et al. compared the impact of invasive diagnostic
techniques (via fiberoptic bronchoscopy) and non-invasive
diagnostic techniques (via quantitative endotracheal
aspirates) on the outcome of patients with VAP. They
found that bronchoscopy led to more frequent changes in
antibiotic therapy than non-invasive techniques, but did
not favorably influence mortality (35).
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Even when combining either non-invasive or invasive
sampling techniques with clinical criteria to improve
diagnostic yield in patients with radiographic infiltrates,
there is a percentage of patients in whom the diagnosis of
pneumonia cannot be established. Thus, the potential of
underdiagnosis might impair the outcome for these
patients. Neverthless, in other settings, the overdiagnosis
of pneumonia might enhance antibiotic consumption,
increase the emergence of resistance, or increase the
likelihood of fungal colonization or infection, and
needlessly increase costs.
De-escalation therapy
Once the microbiological data have become available
and the patient’s response to therapy is evaluated, it is
also necessary to de-escalate therapy in order to avoid
unnecessary prolonged use of an antibiotic of a spectrum
broader than justified by the available information.
Although a de-escalating approach to antibiotic therapy
(i.e. culture-guided treatment) may not help individual
patients, it could benefit the ICU as a whole by reducing
selection pressure for resistance. The use of
microbiological data may also reveal information
important for future patients. The cultures of respiratory
specimens from clinical infection sites can serve as a form
of database for defining local patterns of antibiotic
resistance, which can then guide therapeutic
recommendations.
Considering the importance of adequate initial antibiotic
therapy in critically ill patients with VAP, a de-escalating
strategy (i.e. starting with broad-spectrum antibiotic
therapy followed by narrow-spectrum specific therapy,
according to microbiological results) seems to be the
preferred approach than starting narrow-spectrum therapy
and then broadening the spectrum once culture data
becomes available. Thus, initial broad-spectrum antibiotic
therapy provides maximum benefit for the individual,
severely infected patient, whereas switching to a specific
antibiotic therapy according to microbiological data may
help minimize the risk of emerging resistance (36).
Antibiotic cycling
Strategies such as scheduled changes of antibiotic
regimens or routine microbiological surveillance-guided
changes of antibiotic policy may also reduce the risk of
emerging resistant strains. Kollef et al. (37) have shown
that a planned proactive approach of change by routinely
varying the antibiotic policy (e.g., from using ceftazidime
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to using ciprofloxacin) in an ICU setting may be useful in
preventing the emergence of resistance by reducing the
selection pressure on bacteria. Instead of using a certain
standard antibiotic regimen for a period of time and then
changing to another regimen for the next period, an
alternative approach might be treating consecutive
patients with different antibiotic regimens within the
same time period to reduce selection pressure for highly
resistant nosocomial pathogens within the ward.
The first trials on antibiotic cycling have yielded
conflicting results. Dominguez et al. observed a reduced
rate of Gram-negative resistance in their hematologyoncology unit when comparing four different time
periods with different antibiotic regimens, but also
observed an increase in Gram-positive resistance, which
was mainly due to a marked increase in enterococcal
infections (38).
Of major concern regarding the widespread use of
broad-spectrum empiric therapy in the ICU is the fear of
emergence of multidrug-resistant pathogens. Additional
well-known factors predisposing patients to resistance
are numerous, including prior antibiotic use especially at
suboptimal levels, suboptimal treatment duration, or
prolonged duration of stay in the hospital or ICU (39).

Conclusions
Besides vigorous efforts to improve the procedures
for establishing the diagnosis of VAP, a strategy that
might lower the unacceptably high fatality rate of this
common ICU disease could be the initiation of an
immediate broad-spectrum antibiotic treatment covering
all potential high-risk pathogens in severely ill patients
with suspected VAP.
At present, no antibiotic regimen or combination of
antibiotics could be linked to a sustained better outcome
in severely ill patients with VAP in terms of morbidity and
mortality rates. For this reason, what appears to be
currently needed are well-performed clinical studies
aimed at determining the most effective, least toxic, and
most cost-efficient approaches for the initial empiric
treatment of suspected VAP.
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